Natalie Y. Galanina

Hematology
5115 Centre Ave
Pittsburgh, PA 15232

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.

ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.

Journal: Blood neoplasia
Published: January 20, 2026

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.

Journal: Nature communications
Published: March 24, 2020

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer.

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer.

Journal: Journal for immunotherapy of cancer
Published: February 20, 2019

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Journal: Cancers
Published: November 19, 2018

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Journal: Cancer biology & therapy
Published: October 12, 2018

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.

Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.

Journal: Cancer immunology research
Published: February 27, 2018

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Journal: Blood advances
Published: January 10, 2018

Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.

Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.

Journal: American journal of hematology
Published: April 21, 2017

University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.

Journal: British journal of haematology
Published: April 19, 2017

Emerging role of checkpoint blockade therapy in lymphoma.

Emerging role of checkpoint blockade therapy in lymphoma.

Journal: Therapeutic advances in hematology
Published: February 17, 2017

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

Journal: Blood advances
Published: December 09, 2016

Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.

Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.

Journal: Leukemia & lymphoma
Published: July 15, 2016
Showing 1-12 of 16

Last Updated: 09/26/2026